Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 4/20 | 0.64 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.64 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.64 |
| ▸ | CDK9 | P50750 | 2/20 | 0.64 |
| ▸ | BRD4 | O60885 | 5/20 | 0.61 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.56 |
| ▸ | CDK1 | P06493 | 2/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.52 |
| ▸ | AURKA | O14965 | 2/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.49 |
| ▸ | AXL | P30530 | 2/20 | 0.49 |
| ▸ | GSK3A | P49840 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
| ▸ | BTK | Q06187 | 1/20 | 0.48 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1198375 | 0.88 | SYK (0.67) | CDK2CCNT1CCNE1CDK9BRD4 | |
| SCHEMBL1198508 | 0.83 | CCNT1 (0.71) | CDK2CCNT1CCNE1CDK9BRD4 | |
| SCHEMBL4003367 | 0.82 | BRD4 (0.49) | CDK2CCNT1CCNE1CDK9BRD4 | |
| SCHEMBL1197107 | 0.81 | AURKA (0.70) | AURKAAURKBGSK3AGSK3BSYK | |
| SCHEMBL1198364 | 0.81 | SYK (0.67) | CDK2CCNT1CCNE1CDK9BRD4 | |
| SCHEMBL1198512 | 0.81 | SYK (0.68) | CDK2NTRK1CDK1AURKAAURKB | |
| SCHEMBL1197568 | 0.81 | FLT3 (0.57) | CDK2CCNT1CCNE1CDK9BRD4 | |
| SCHEMBL1197345 | 0.80 | PAK1 (0.65) | CDK2CCNT1CCNE1CDK9BRD4 | |
| SCHEMBL1196911 | 0.79 | CDK2 (0.58) | CDK2CCNT1CCNE1CDK9BRD4 | |
| SCHEMBL1197088 | 0.78 | SYK (0.60) | CDK2CCNT1CCNE1CDK9BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7834024-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2010-11-16 | — | — | US | claimed |
| US-20080260754-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | claimed |
| US-8299087-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-20110027856-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| US-7834024-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-20080260754-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | disclosed |
| WO-2008118823-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080260754-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | CDK2 236/4885CCNT1 1524/4885CCNE1 2121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.